# Cannabis News and Regulatory Roundup: Comparative transcriptome analysis reveals p… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-news-and-regulatory-roundup-comparative-transcriptome-analysis-sep-2026/ > **Published:** 2026-09-15T19:30:03-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:32-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic This curated cannabis news and regulatory roundup delivers practical physician analysis of 3 timely developments across cannabis policy, administrative rulemaking, and consumer health protections. By evaluating these updates within their specific regulatory and clinical contexts, healthcare providers and registered patients can separate genuine progress from speculative marketing claims. Staying informed about laboratory testing standards, licensing rules, and emerging data ensures that clinical counseling remains grounded in verified evidence, prioritizing patient safety and therapeutic efficacy above all. Grounding clinical recommendations in primary data ensures that patient counseling remains calibrated, safe, and medically sound across all treatment pathways. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Comparative transcriptome analysis reveals putativ. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42741330/) A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us The comparative transcriptome analysis identified 1314 genes upregulated in female cannabis flowers, with 16 transcription factors (TFs) linked to CBD biosynthesis. In a study of 15,000 adolescents, perceived social connectedness was associated with lower substance use, moderated by perceptions of parental and friend disapproval. A longitudinal study of 23 bipolar disorder patients revealed that cannabis users had disrupted endocannabinoid trajectories, with no significant decline in anandamide and 2-arachidonoglycerol levels during recovery from mania. Why This Matters Understanding the genetic regulation of CBD production can enhance cannabis breeding for therapeutic use. Insights into social connectedness and substance use can inform prevention strategies, while monitoring endocannabinoid levels in bipolar disorder patients may guide treatment approaches. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesSeptember 15, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Comparative transcriptome analysis revea (Li et al., PubMed) [DOI: 10.3389/fpls.2026.1914974 | PMID: 42741330]Study 2Perceived Social Connectedness and Subst (Ballard et al., PubMed) [DOI: 10.1007/s11121-026-01981-5 | PMID: 42736530]Study 3Plasma endocannabinoid levels in bipolar (Ochandiano et al., PubMed) [DOI: 10.1016/j.jad.2026.122483 | PMID: 42735776] Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Comparative transcriptome analysis reveals putativ](#digest-card-2-digest-card-1-comparative-transcriptome-analysis-reveals-putativ) - [Digest Card 2 | Perceived Social Connectedness and Substance Use a](#digest-card-3-digest-card-2-perceived-social-connectedness-and-substance-use-a) - [Digest Card 3 | Plasma endocannabinoid levels in bipolar disorder:](#digest-card-4-digest-card-3-plasma-endocannabinoid-levels-in-bipolar-disorder) Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Comparative transcriptome analysis reveals putativ **Title & Source:** [Comparative transcriptome analysis reveals putative transcription factors components of the regulatory network for cannabidiol biosynthesis in Cannabis sativa L.](https://pubmed.ncbi.nlm.nih.gov/42741330/) (*PubMed*, 2026) **Lead Authors & Identifiers:** Ying Li, Huijuan Tang, Tian Zhang, Xiaolin Li, Bowen Zheng, Meng Cheng, Guang Yang, Gen Pan. | **Primary Record:** DOI: 10.3389/fpls.2026.1914974 | PMID: 42741330 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** In this evaluation by Li and colleagues, Cannabidiol (CBD), a unique secondary metabolite of Cannabis sativa L. (cannabis), is widely used in medicine, food, cosmetics, and forage. Elucidation of the transcriptional regulation mechanism can provide a theoretical basis for molecular breeding with higher CBD content. However, the regulatory network for cannabidiol biosynthesis in cannabis is largely unknown. Transcriptome analysis of four cannabis tissues was conducted to screen differentially expressed genes. Short time-series expression miner (STEM) analysis combined with strain-specific expression correlation analysis was performed to filter core transcription factors (TFs) associated with CBD biosynthetic enzyme genes. Yeast one-hybrid and yeast two-hybrid assays were applied to verify the binding and protein interaction relationships of key TFs, and subcellular localization assay was performed in tobacco leaf. A total of 1314 genes specifically upregulated in female flowers were identified by transcriptome analysis of four different tissues with distinct CBD contents and clustered into 19 profiles using short time-series expression miner (STEM) analysis. Profile 8, including 16 TFs and 6 enzyme genes related to the CBD biosynthesis pathway, demonstrated similar trends in the CBD contents of the four tissues. Among the 16 TFs, 7 exhibited similar strain-specific expression profiles and their expression levels positively correlated with those of the six enzyme genes. Moreover, a yeast one-hybrid assay found that CsMYB6 and CsMYB29 bind to the promoters of four and two CBD biosynthetic enzyme genes, respectively. Meanwhile, a yeast two-hybrid assay revealed that CsMYB6 interacts with two regulators of CBD biosynthesis, CsMYB1 and CsWRKY1, while CsMYB29 interacts with CsWRKY1. In addition, CsMYB29 and CsMYB6 were localized in the nuclei. In summary, the two TFs, CsMYB6 and CsMYB29, identified in this study provide valuable insight into the complex regulatory mechanisms of CBD production in cannabis and offer a genetic resource for the genetic improvement of CBD content. Understanding this publication requires placing it within the broader framework of administrative implementation, market dynamics, and regulatory policy. primary clinical literature reproducible evidence from media framing. **2. Detailed Findings & Primary Data:** The study identified 1314 genes specifically upregulated in female flowers of Cannabis sativa, clustered into 19 profiles. Profile 8 included 16 TFs and 6 enzyme genes related to CBD biosynthesis, with 7 TFs showing strain-specific expression correlating positively with enzyme gene expression. Yeast assays confirmed that CsMYB6 and CsMYB29 interact with key CBD biosynthetic regulators, providing insights into the regulatory mechanisms of CBD production. **3. Dr. Caplan’s Clinical & Practical Guidance:** From a clinical perspective, this update offers valuable insights for patient counseling. Patients and healthcare operators navigating evolving regulations benefit from focusing on product testing transparency, verified licensing, and patient protections. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes. **4. Study Boundaries & Methodological Limits:** As with all rapidly evolving administrative updates and news reports, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations. Digest Card 2 | Perceived Social Connectedness and Substance Use a **Title & Source:** [Perceived Social Connectedness and Substance Use among Adolescents and Young Adults in North Carolina.](https://pubmed.ncbi.nlm.nih.gov/42736530/) (*PubMed*, 2026Sep14) **Lead Authors & Identifiers:** Parissa J Ballard, Thomas P McCoy, Jonna Lasley, Melinda M Pankratz, Kathleen L Egan, Justin B Moore, Veronica Cole, Renata Yassa, Kimberly G Wagoner, Jennifer Cornacchione Ross, Scott D Rhodes. | **Primary Record:** DOI: 10.1007/s11121-026-01981-5 | PMID: 42736530 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** In this evaluation by Ballard and colleagues, Substance use during adolescence and young adulthood is a persistent public health problem. Social connectedness is associated with health, but research is needed to clarify the potential protective role of different aspects of social connectedness in primary prevention of substance use behaviors. This study explores associations between perceived social connectedness to two developmentally important social groups (friends and family) and various substances (alcohol, e-cigarettes, cigarettes, cannabis, and prescription medication) among adolescents and young adults. In addition, it examines how descriptive and injunctive norms within social groups affect associations between perceived social connectedness and substance use behaviors among adolescents and young adults. A statewide survey was conducted among 15,000 adolescents and young adults (12-25 years old, 52.6% female, 69.6% White) in North Carolina. Perceived social connectedness and substance use were assessed cross-sectionally, along with potential moderators (perceived friend and parent substance use and disapproval). Logistic regression was used to model associations with substance use. Moderation was examined with a regions-of-significance approach. Overall, perceived social connectedness was associated with lower odds of using most substances among adolescents and young adults. However, associations were moderated by perceptions of parental and friend substance disapproval and to a lesser extent by perceptions of parental and friend substance use behaviors. Findings suggest perceived connectedness to friends could potentially protect against substance use in the context of high perceived friend disapproval, whereas perceived connectedness to family is complex and may protect against substance use in the context of moderate/lower perceived parental disapproval of substance use. Longitudinal research is needed to understand the direction of associations with additional measures of social connectedness to help elucidate which aspects are protective and which are risky for adolescent and young adult substance use. Understanding this publication requires placing it within the broader framework of administrative implementation, market dynamics, and regulatory policy. primary clinical literature reproducible evidence from media framing. **2. Detailed Findings & Primary Data:** Among 15,000 adolescents and young adults surveyed, perceived social connectedness was linked to lower odds of substance use across various substances. The study found that high perceived friend disapproval could enhance the protective effect of connectedness to friends, while family connectedness showed a more complex relationship depending on parental disapproval levels. Logistic regression analysis indicated significant moderation effects of social norms on substance use behaviors. **3. Dr. Caplan’s Clinical & Practical Guidance:** From a clinical perspective, this update offers valuable insights for patient counseling. Patients and healthcare operators navigating evolving regulations benefit from focusing on product testing transparency, verified licensing, and patient protections. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes. **4. Study Boundaries & Methodological Limits:** As with all rapidly evolving administrative updates and news reports, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations. Digest Card 3 | Plasma endocannabinoid levels in bipolar disorder: **Title & Source:** [Plasma endocannabinoid levels in bipolar disorder: Differences between manic and euthymic states and the impact of cannabis use.](https://pubmed.ncbi.nlm.nih.gov/42735776/) (*PubMed*, 2026Sep14) **Lead Authors & Identifiers:** Iñaki Ochandiano, Pavel Powlowski, Helena Andreu, Luis Olivier, Guadalupe Cabeza, Anna Gimenez-Palomo, Mariona Guitart, Gloria Garrabou, Andrea Escelsior, Miquel Bioque, Marc Valentí, Michael Berk, Ana Cristina Andreazza, Eduard Vieta, Ruth Alexandra Ross, Isabella Pacchiarotti. | **Primary Record:** DOI: 10.1016/j.jad.2026.122483 | PMID: 42735776 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** In this evaluation by Ochandiano and colleagues, The endocannabinoid system (ECS) is a key regulator of mood homeostasis, but its longitudinal dynamics during an acute manic episode until the clinical recovery in bipolar disorder (BD) and the specific influence of cannabis use remain poorly characterized. We conducted a longitudinal study of 23 patients with BD I followed from acute mania (T0) to clinical stabilization (T1). Plasma AEA and 2-AG were quantified via LC-MS/MS at T0 and T1. Patients were divided into cannabis users and non-cannabis users for further analyses. Linear mixed-effects models assessed the interaction between cannabis use and timepoint on endocannabinoid (eCB) trajectories. Non-cannabis users exhibited a significant decline in both anandamide (AEA) and 2-arachidonoglycerol (2-AG) levels during the transition to euthymia (p  --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).